pioglitazone has been researched along with Benign Neoplasms in 21 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Among 193,099 persons in the bladder cancer cohort, 34,181 (18%) received pioglitazone (median duration, 2." | 7.81 | Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes. ( Bilker, W; Ehrlich, SF; Ferrara, A; Habel, LA; Hedderson, MM; Lewis, JD; Mamtani, R; Nessel, L; Peng, T; Quesenberry, CP; Strom, BL; Van Den Eeden, SK; Vaughn, DJ, 2015) |
| " Hyperglycemia is an on-target side effect of many inhibitors of PI3K/Akt signaling including the specific PI3K inhibitor PX-866." | 7.75 | Peroxisome proliferator-activated receptor gamma agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity. ( Halter, RJ; Ihle, NT; Kirkpatrick, L; Lemos, R; Oh, J; Powis, G; Schwartz, D; Wipf, P, 2009) |
| "The combined treatment with INS 18 U/kg + PIO 5 mg/kg was more effective in preventing advanced cachexia in TB rats than each treatment alone, emerging as the best approach, considering the lower dosage and higher efficacy." | 5.91 | Insulin in combination with pioglitazone prevents advanced cachexia in 256-Walker tumor-bearing rats: effect is greater than treatment alone and is associated with improved insulin sensitivity. ( Bazotte, RB; Bertolini, GL; Biazi, GR; Cassolla, P; de Souza Galia, WB; de Souza, HM; Diaz, BF; Ferraz, LS; Frasson, IG; Kurauti, MA; Mareze-Costa, CE; Marmentini, C; Miksza, DR; Peres, SB, 2023) |
| "Among 193,099 persons in the bladder cancer cohort, 34,181 (18%) received pioglitazone (median duration, 2." | 3.81 | Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes. ( Bilker, W; Ehrlich, SF; Ferrara, A; Habel, LA; Hedderson, MM; Lewis, JD; Mamtani, R; Nessel, L; Peng, T; Quesenberry, CP; Strom, BL; Van Den Eeden, SK; Vaughn, DJ, 2015) |
| " Hyperglycemia is an on-target side effect of many inhibitors of PI3K/Akt signaling including the specific PI3K inhibitor PX-866." | 3.75 | Peroxisome proliferator-activated receptor gamma agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity. ( Halter, RJ; Ihle, NT; Kirkpatrick, L; Lemos, R; Oh, J; Powis, G; Schwartz, D; Wipf, P, 2009) |
| "Development of agents for cancer prevention has been particularly challenging for two main reasons." | 2.53 | Repurposing Drugs for Cancer Prevention. ( Lee, DK; Szabo, E, 2016) |
| "Pioglitazone was associated with increased incidence of melanoma and non-Hodgkin lymphoma and decreased risk of renal cancer in one cohort study." | 2.49 | Pioglitazone and cancer: angel or demon? ( Elisaf, MS; Kostapanos, MS; Mikhailidis, DP, 2013) |
| "The combined treatment with INS 18 U/kg + PIO 5 mg/kg was more effective in preventing advanced cachexia in TB rats than each treatment alone, emerging as the best approach, considering the lower dosage and higher efficacy." | 1.91 | Insulin in combination with pioglitazone prevents advanced cachexia in 256-Walker tumor-bearing rats: effect is greater than treatment alone and is associated with improved insulin sensitivity. ( Bazotte, RB; Bertolini, GL; Biazi, GR; Cassolla, P; de Souza Galia, WB; de Souza, HM; Diaz, BF; Ferraz, LS; Frasson, IG; Kurauti, MA; Mareze-Costa, CE; Marmentini, C; Miksza, DR; Peres, SB, 2023) |
| "Unlike tumors, the RAW264." | 1.42 | The effect of PPAR-γ agonist on (18)F-FDG PET imaging for differentiating tumors and inflammation lesions. ( Cheong, SJ; Jeong, HJ; Kim, EM; Lee, CM; Lim, ST; Sohn, MH, 2015) |
| "The effects of TZDs on cancer risk in humans needs to be resolved as these drugs are prescribed for long periods of time in patients with diabetes." | 1.34 | Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System. ( Littenberg, B; MacLean, CD; Ramos-Nino, ME, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (33.33) | 29.6817 |
| 2010's | 8 (38.10) | 24.3611 |
| 2020's | 6 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Willson, TM | 1 |
| Brown, PJ | 1 |
| Sternbach, DD | 1 |
| Henke, BR | 1 |
| Joshi, H | 1 |
| Patil, V | 1 |
| Tilekar, K | 2 |
| Upadhyay, N | 2 |
| Gota, V | 1 |
| Ramaa, CS | 1 |
| Hess, JD | 1 |
| Bianco, AL | 1 |
| Schweipert, M | 1 |
| Laghezza, A | 1 |
| Loiodice, F | 1 |
| Meyer-Almes, FJ | 1 |
| Aguilera, RJ | 1 |
| Lavecchia, A | 1 |
| C S, R | 1 |
| Placha, W | 1 |
| Zagajewski, J | 1 |
| Suder, P | 1 |
| Piwowar, M | 1 |
| Miksza, DR | 1 |
| Biazi, GR | 1 |
| Frasson, IG | 1 |
| de Souza Galia, WB | 1 |
| Ferraz, LS | 1 |
| Diaz, BF | 1 |
| Kurauti, MA | 1 |
| Marmentini, C | 1 |
| Mareze-Costa, CE | 1 |
| Peres, SB | 1 |
| Cassolla, P | 1 |
| Bertolini, GL | 1 |
| Bazotte, RB | 1 |
| de Souza, HM | 1 |
| Kalra, S | 1 |
| Priya, G | 1 |
| Bhattacharya, S | 1 |
| Sahay, R | 1 |
| Szychowski, KA | 1 |
| Skóra, B | 1 |
| Kryshchyshyn-Dylevych, A | 1 |
| Kaminskyy, D | 1 |
| Khyluk, D | 1 |
| Lesyk, R | 1 |
| Srivastava, N | 1 |
| Kollipara, RK | 1 |
| Singh, DK | 1 |
| Sudderth, J | 1 |
| Hu, Z | 1 |
| Nguyen, H | 1 |
| Wang, S | 1 |
| Humphries, CG | 1 |
| Carstens, R | 1 |
| Huffman, KE | 1 |
| DeBerardinis, RJ | 1 |
| Kittler, R | 1 |
| Cheong, SJ | 1 |
| Lee, CM | 1 |
| Kim, EM | 1 |
| Lim, ST | 1 |
| Sohn, MH | 1 |
| Jeong, HJ | 1 |
| Lewis, JD | 2 |
| Habel, LA | 2 |
| Quesenberry, CP | 2 |
| Strom, BL | 2 |
| Peng, T | 2 |
| Hedderson, MM | 1 |
| Ehrlich, SF | 2 |
| Mamtani, R | 1 |
| Bilker, W | 1 |
| Vaughn, DJ | 1 |
| Nessel, L | 1 |
| Van Den Eeden, SK | 2 |
| Ferrara, A | 2 |
| Lee, DK | 1 |
| Szabo, E | 1 |
| Yamamoto, Y | 1 |
| Ono, T | 1 |
| Dhar, DK | 1 |
| Yamanoi, A | 1 |
| Tachibana, M | 1 |
| Tanaka, T | 1 |
| Nagasue, N | 1 |
| Ihle, NT | 1 |
| Lemos, R | 1 |
| Schwartz, D | 1 |
| Oh, J | 1 |
| Halter, RJ | 1 |
| Wipf, P | 1 |
| Kirkpatrick, L | 1 |
| Powis, G | 1 |
| Punthakee, Z | 1 |
| Bosch, J | 1 |
| Dagenais, G | 1 |
| Diaz, R | 1 |
| Holman, R | 1 |
| Probstfield, J | 1 |
| Ramachandran, A | 1 |
| Riddle, M | 1 |
| Rydén, LE | 1 |
| Zinman, B | 1 |
| Afzal, R | 1 |
| Yusuf, S | 1 |
| Gerstein, H | 1 |
| Banerjee, S | 1 |
| Kostapanos, MS | 1 |
| Elisaf, MS | 1 |
| Mikhailidis, DP | 1 |
| Gehrmann, M | 1 |
| Brunner, M | 1 |
| Pfister, K | 1 |
| Reichle, A | 1 |
| Kremmer, E | 1 |
| Multhoff, G | 1 |
| Nakata, S | 1 |
| Yoshida, T | 1 |
| Shiraishi, T | 1 |
| Horinaka, M | 1 |
| Kouhara, J | 1 |
| Wakada, M | 1 |
| Sakai, T | 1 |
| Ramos-Nino, ME | 1 |
| MacLean, CD | 1 |
| Littenberg, B | 1 |
| Mrówka, P | 1 |
| Głodkowska, E | 1 |
| Młynarczuk-Biały, I | 1 |
| Biały, L | 1 |
| Kuckelkorn, U | 1 |
| Nowis, D | 1 |
| Makowski, M | 1 |
| Legat, M | 1 |
| Gołab, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Cohort Study of Pioglitazone and Bladder Cancer in Patients With Diabetes[NCT01637935] | 193,099 participants (Actual) | Observational | 2004-07-31 | Completed | |||
| AVANDIA CV Outcomes Study: Thiazolidinedione Intervention With Vitamin D Evaluation (TIDE) A Multicenter Randomized Double-Blind Placebo-Controlled Trial of a Thiazolidinedione or Placebo and of Vitamin D or Placebo In People With Type 2 Diabetes at Risk [NCT00879970] | Phase 4 | 1,332 participants (Actual) | Interventional | 2009-05-31 | Terminated (stopped due to FDA has placed the trial on full clinical hold.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Incident bladder cancers were identified from January 1, 1997 to December 31, 2012. (NCT01637935)
Timeframe: January 1, 1997 to December 31, 2012
| Intervention | events per 100,000 person years (Number) |
|---|---|
| Pioglitazone Exposed Group | 89.8 |
| Pioglitazone Unexposed Group | 75.9 |
(NCT01637935)
Timeframe: January 1, 1997 to December 31, 2012
| Intervention | events per 100,000 person years (Number) | ||
|---|---|---|---|
| 1 - 14000 mg | 14001 - 40000 mg | >40000 mg | |
| Pioglitazone Exposed Group | 69.1 | 96.9 | 101.4 |
| Pioglitazone Unexposed Group | NA | NA | NA |
(NCT01637935)
Timeframe: January 1, 1997 to December 31, 2012
| Intervention | events per 100,000 person years (Number) | ||
|---|---|---|---|
| Less than 1.5 years | 1.5 - 4.0 years | More than 4 years | |
| Pioglitazone Exposed Group | 67.5 | 88.4 | 113.7 |
| Pioglitazone Unexposed Group | NA | NA | NA |
(NCT01637935)
Timeframe: January 1, 1997 to December 31, 2012
| Intervention | events per 100,000 person years (Number) | ||
|---|---|---|---|
| Less than 4.5 years | 4.5 -8.5 years | More than 8.0 years | |
| Pioglitazone Exposed Group | 68.2 | 111.6 | 125.8 |
| Pioglitazone Unexposed Group | NA | NA | NA |
(NCT01637935)
Timeframe: January 1, 1997 to December 31, 2012
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| PUNLMP | In situ | Local | Regional | Distant | Undetermined | |
| Pioglitazone Exposed Group | 1 | 50 | 40 | 4 | 2 | 3 |
| Pioglitazone Unexposed Group | 1 | 49 | 38 | 6 | 3 | 3 |
Fracture is defined as a medical condition in which there is a break in the continuity of the bone. Fractures are defined as those breaks that are self reported plus confirmed by an X-ray. Data regarding all occurrences of any fracture were adjudicated by the EAC and sent to the IDMC on a regular basis for unblinded review. (NCT00879970)
Timeframe: From Randomization at Visit 3 to Final Visit (up to 162 days)
| Intervention | participants (Number) |
|---|---|
| Placebo | 2 |
| Pioglitazone | 2 |
| Rosiglitazone | 3 |
| VITAMIN D PLACEBO | 3 |
| VITAMIN D | 3 |
Revascularization is defined as any surgical procedure for the provision of a new, additional, or augmented blood supply to heart muscle. Data regarding the need for any revascularization were adjudicated by the EAC and sent to the data monitoring committee (IDMC) on a regular basis for unblinded review. (NCT00879970)
Timeframe: From Randomization at Visit 3 to Final Visit (up to 162 days)
| Intervention | participants (Number) |
|---|---|
| Placebo | 6 |
| Pioglitazone | 3 |
| Rosiglitazone | 5 |
| VITAMIN D PLACEBO | 7 |
| VITAMIN D | 5 |
Clinical proteinuria is defined as a laboratory detection of urinary protein excretion > 0.5 grams (g) per 24 hours; spot urine analysis for albumin:creatinine ratio >=300 milligrams/g; timed urine collection for albumin excretion >=200 µg/minute or >=300 mg/24 hours. Clinical proteinuria data were obtained from outcomes reported by the site. (NCT00879970)
Timeframe: From Randomization at Visit 3 to Final Visit (up to 162 days)
| Intervention | participants (Number) |
|---|---|
| Placebo | 1 |
| Pioglitazone | 0 |
| Rosiglitazone | 0 |
| VITAMIN D PLACEBO | NA |
| VITAMIN D | NA |
The components of the composite microvascular outcome are retinopathy, decline in eGFR, vitrectomy, and renal replacement surgery. Retinopathy is defined as damage to the inner lining of the eye (retina). Decline in eGFR is defined as a >=30% reduction in kidney function. Vitrectomy is a surgery to remove some or all of the fluid (vitreous humor) from the eye. Renal replacement therapy includes all the life-supporting treatments for renal failure. Data regarding the number of participants with changes in micro blood vessels (composite microvascular outcome) were collected at each visit. (NCT00879970)
Timeframe: From Randomization at Visit 3 to Final Visit (up to 162 days)
| Intervention | participants (Number) |
|---|---|
| Placebo | 21 |
| Pioglitazone | 8 |
| Rosiglitazone | 9 |
| VITAMIN D PLACEBO | 18 |
| VITAMIN D | 18 |
"Liver function tests are groups of clinical biochemistry laboratory blood assays designed to give information about the health of the liver. Liver function test abnormal and hepatic enzyme increased were obtained from adverse event data as reported by investigators based on the reference range of the reporting local laboratory methodology. The vitamin D arm was not analyzed for this outcome measure." (NCT00879970)
Timeframe: From Randomization at Visit 3 to Final Visit (up to 162 days)
| Intervention | participants (Number) |
|---|---|
| Placebo | 1 |
| Pioglitazone | 0 |
| Rosiglitazone | 1 |
| VITAMIN D PLACEBO | NA |
| VITAMIN D | NA |
Data regarding the need for hospitalization for any reason were collected and were then forwarded to the independent data monitoring committee (IDMC) on a regular basis for unblinded review. (NCT00879970)
Timeframe: From Randomization at Visit 3 to Final Visit (up to 162 days)
| Intervention | participants (Number) |
|---|---|
| Placebo | 31 |
| Pioglitazone | 16 |
| Rosiglitazone | 24 |
| VITAMIN D PLACEBO | 19 |
| VITAMIN D | 32 |
Severe hypoglycemia is defined as hypoglycemia requiring assistance from another person with either a documented plasma glucose <=36 mg/deciliter (2.0 millimole per liter [mmol/L]) or prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration. Hypoglycemia data were obtained from outcomes reported by the site. Data regarding hypoglycemia were adjudicated by the EAC and sent to the IDMC on a regular basis for unblinded review. (NCT00879970)
Timeframe: From Randomization at Visit 3 to Final Visit (up to 162 days)
| Intervention | participants (Number) |
|---|---|
| Placebo | 0 |
| Pioglitazone | 2 |
| Rosiglitazone | 1 |
| VITAMIN D PLACEBO | 0 |
| VITAMIN D | 3 |
CHF is a condition in which the heart is not able to pump adequate blood to meet the body's needs. Shortness of breath is defined as difficulty in breathing. Pneumonia is an infection of the lungs, caused by various microorganisms. Angina is defined as severe chest pain due to lack of adequate blood supply of the heart muscle because of obstruction/spasm of the heart's blood vessels. Data regarding the need for hospitalization due to any of these reasons were adjudicated by the EAC and sent to the IDMC on a regular basis for unblinded review. (NCT00879970)
Timeframe: From Randomization at Visit 3 to Final Visit (up to 162 days)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| CHF | Shortness of breath | Pneumonia | Angina | |
| Pioglitazone | 2 | 1 | 1 | 1 |
| Placebo | 1 | 0 | 0 | 3 |
| Rosiglitazone | 0 | 2 | 0 | 1 |
| VITAMIN D | 2 | 1 | 0 | NA |
| VITAMIN D PLACEBO | 0 | 0 | 0 | NA |
Retinopathy is defined as damage to the inner lining of the eye (retina). Decline in eGFR is defined as a >=30% reduction in kidney function. Vitrectomy is a surgery to remove some or all of the fluid (vitreous humor) from the eye. Renal replacement therapy includes all the life-supporting treatments for renal failure. Data on the number of participants with all of these microvascular outcomes were collected at each visit. Data regarding the number of participants with these microvascular outcomes were adjudicated by the EAC and sent to the IDMC on a regular basis for unblinded review. (NCT00879970)
Timeframe: From Randomization at Visit 3 to Final Visit (up to 162 days)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Retinopathy Requiring Laser Therapy | Decline in eGFR >=30% | Vitrectomy | Renal Replacement Therapy | |
| Pioglitazone | 0 | 8 | 0 | 0 |
| Placebo | 1 | 20 | 0 | 0 |
| Rosiglitazone | 0 | 9 | 0 | 0 |
| VITAMIN D | 0 | 18 | 0 | 0 |
| VITAMIN D PLACEBO | 0 | 18 | 0 | 0 |
An event adjudication committee (EAC) adjudicated all occurrences of the components of the composite cardiovascular (CV; related to heart) outcome for TZD. Components are the first occurrence of cardiovascular death for which a non-heart-related cause has not been identified; non-fatal myocardial infarction (MI) (death of heart muscle from sudden blockage of a coronary artery by blood clot not leading to death); and non-fatal stroke (rapidly developing loss of brain function[s] due to disturbance in the blood supply to the brain not leading to death). (NCT00879970)
Timeframe: From Randomization at Visit 3 up to the Final Visit (average of 162 days)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| CV Death/Non-Fatal MI/Non-Fatal Stroke | CV Death | Non-Fatal MI | Non-Fatal Stroke | |
| Pioglitazone (PIO) | 2 | 0 | 0 | 2 |
| Placebo | 5 | 1 | 2 | 2 |
| Rosiglitazone (RSG) | 1 | 0 | 1 | 0 |
| Vitamin D | 2 | 0 | 1 | 1 |
| Vitamin D Placebo | 3 | 1 | 1 | 1 |
An EAC adjudicated all occurrences of the components of the composite outcome for vitamin D. Components are the first occurrence of death or cancer requiring hospitalization, treatment with medicines (chemotherapy), or surgery. (NCT00879970)
Timeframe: From Randomization at Visit 3 to Final Visit (up to 162 days)
| Intervention | participants (Number) | ||
|---|---|---|---|
| Death or serious cancer | All death | Serious cancer | |
| Pioglitzaone | 3 | 1 | 2 |
| Placebo | 6 | 4 | 2 |
| Rosiglitazone | 1 | 1 | 0 |
| Vitamin D | 2 | 0 | 2 |
| Vitamin D Placebo | 3 | 2 | 1 |
4 reviews available for pioglitazone and Benign Neoplasms
| Article | Year |
|---|---|
The PPARs: from orphan receptors to drug discovery.
Topics: Animals; Diabetes Mellitus; Drug Design; Humans; Hyperlipidemias; Hypertension; Inflammation; Ligand | 2000 |
Oncocrinology.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Endocri | 2020 |
Repurposing Drugs for Cancer Prevention.
Topics: Anticarcinogenic Agents; Aspirin; Drug Repositioning; Humans; Metformin; Neoplasms; Pioglitazone; Th | 2016 |
Pioglitazone and cancer: angel or demon?
Topics: Animals; Carcinogens; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Neoplasms; Pioglitazon | 2013 |
1 trial available for pioglitazone and Benign Neoplasms
| Article | Year |
|---|---|
Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial.
Topics: Aged; Cardiovascular Diseases; Cholecalciferol; Combined Modality Therapy; Diabetes Mellitus, Type 2 | 2012 |
16 other studies available for pioglitazone and Benign Neoplasms
| Article | Year |
|---|---|
Benzylidene thiazolidinediones: Synthesis, in vitro investigations of antiproliferative mechanisms and in vivo efficacy determination in combination with Imatinib.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzylide | 2020 |
Thiazolidinedione "Magic Bullets" Simultaneously Targeting PPARγ and HDACs: Design, Synthesis, and Investigations of their
Topics: Animals; Antineoplastic Agents; Apoptosis; Binding Sites; Cell Cycle Checkpoints; Cell Line, Tumor; | 2021 |
A method of isolating and analysing drugs from cancer cells for preclinical research.
Topics: Chromatography, High Pressure Liquid; Cytostatic Agents; Fibric Acids; Hydroxymethylglutaryl-CoA Red | 2022 |
Insulin in combination with pioglitazone prevents advanced cachexia in 256-Walker tumor-bearing rats: effect is greater than treatment alone and is associated with improved insulin sensitivity.
Topics: Animals; Cachexia; Hypoglycemic Agents; Insulin; Insulin Resistance; Neoplasms; Pioglitazone; Rats; | 2023 |
4-thiazolidinone-based derivatives rosiglitazone and pioglitazone affect the expression of antioxidant enzymes in different human cell lines.
Topics: A549 Cells; Antioxidants; Apoptosis; Caco-2 Cells; Caspase 3; Cell Line; Cell Line, Tumor; Humans; N | 2021 |
Inhibition of cancer cell proliferation by PPARγ is mediated by a metabolic switch that increases reactive oxygen species levels.
Topics: Animals; Antineoplastic Agents; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Fatty | 2014 |
The effect of PPAR-γ agonist on (18)F-FDG PET imaging for differentiating tumors and inflammation lesions.
Topics: Anilides; Animals; Biological Transport; Cell Line, Tumor; Diagnosis, Differential; Female; Fluorode | 2015 |
Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes.
Topics: Adult; Aged, 80 and over; Case-Control Studies; Cohort Studies; Diabetes Mellitus, Type 2; Female; H | 2015 |
Role of peroxisome proliferator-activated receptor-gamma (PPARgamma) during liver regeneration in rats.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Differentiation; Cell Proliferation; Enzyme-Linked I | 2008 |
Peroxisome proliferator-activated receptor gamma agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Disease Progression; Glucose; Glucose Transport Pr | 2009 |
Cohort study of pioglitazone and cancer incidence in patients with diabetes.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Neop | 2011 |
Pioglitazone safe, so save.
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug | 2012 |
Differential up-regulation of cytosolic and membrane-bound heat shock protein 70 in tumor cells by anti-inflammatory drugs.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apoptosis; | 2004 |
15-Deoxy-Delta12,14-prostaglandin J(2) induces death receptor 5 expression through mRNA stabilization independently of PPARgamma and potentiates TRAIL-induced apoptosis.
Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosi | 2006 |
Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System.
Topics: Age Distribution; Causality; Comorbidity; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female | 2007 |
Pioglitazone, a PPAR-gamma ligand, exerts cytostatic/cytotoxic effects against cancer cells, that do not result from inhibition of proteasome.
Topics: Cell Line, Tumor; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p27; Cytostatic Agents; Dose-Response | 2008 |